BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Park JH, Kim HY, Lee A, Seo YK, Kim IH, Park ET, Kang MS, Park SJ, Park S. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. Int J Radiat Oncol Biol Phys 2021;110:510-20. [PMID: 33383126 DOI: 10.1016/j.ijrobp.2020.12.031] [Reference Citation Analysis]
2 Zhu L, Yu X, Wang L, Liu J, Qu Z, Zhang H, Li L, Chen J, Zhou Q. Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges. Oncogenesis 2021;10:47. [PMID: 34247198 DOI: 10.1038/s41389-021-00335-w] [Reference Citation Analysis]
3 Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
4 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
5 Choi C, Cho Y, Son A, Shin SW, Lee YJ, Park HC. Therapeutic Potential of (-)-Agelamide D, a Diterpene Alkaloid from the Marine Sponge Agelas sp., as a Natural Radiosensitizer in Hepatocellular Carcinoma Models. Mar Drugs 2020;18:E500. [PMID: 33003597 DOI: 10.3390/md18100500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Pourhamzeh M, Asadian S, Mirzaei H, Minaei A, Shahriari E, Shpichka A, Es HA, Timashev P, Hassan M, Vosough M. Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma. Mol Cell Biochem 2022. [PMID: 35708866 DOI: 10.1007/s11010-022-04483-4] [Reference Citation Analysis]
7 Kim KJ, Lee HW, Seong J. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol. 2020;. [PMID: 33217056 DOI: 10.1111/jgh.15319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Dai Y, Qiang W, Lin K, Gui Y, Lan X, Wang D. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:967-79. [PMID: 33089373 DOI: 10.1007/s00262-020-02743-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Quagliariello V, Passariello M, Rea D, Barbieri A, Iovine M, Bonelli A, Caronna A, Botti G, De Lorenzo C, Maurea N. Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. J Pers Med 2020;10:E179. [PMID: 33086484 DOI: 10.3390/jpm10040179] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
10 Yang K, Choi C, Cho H, Ahn WG, Kim SY, Shin SW, Kim Y, Jang T, Lee N, Park HC. Antigen-Capturing Mesoporous Silica Nanoparticles Enhance the Radiation-Induced Abscopal Effect in Murine Hepatocellular Carcinoma Hepa1-6 Models. Pharmaceutics 2021;13:1811. [PMID: 34834226 DOI: 10.3390/pharmaceutics13111811] [Reference Citation Analysis]
11 Shin SW, Yang K, Lee M, Moon J, Son A, Kim Y, Choi S, Kim DH, Choi C, Lee N, Park HC. Manganese Ferrite Nanoparticles Enhance the Sensitivity of Hepa1-6 Hepatocellular Carcinoma to Radiation by Remodeling Tumor Microenvironments. Int J Mol Sci 2021;22:2637. [PMID: 33807943 DOI: 10.3390/ijms22052637] [Reference Citation Analysis]
12 Qian Y, Gong L, Li S, Mao K, Li X, Liao G. Case Report: Radiotherapy Plus Immunotherapy and Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma With a Right Atrium and Inferior Vena Cava Tumor Thrombus. Front Oncol 2022;12:879454. [DOI: 10.3389/fonc.2022.879454] [Reference Citation Analysis]
13 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Xu LB, Zhao ZG, Xu SF, Zhang XX, Liu T, Jing CY, Zhang SG, Yu SJ. The landscape of gene mutations and clinical significance of tumor mutation burden in patients with soft tissue sarcoma who underwent surgical resection and received conventional adjuvant therapy. Int J Biol Markers 2020;35:14-22. [PMID: 32520634 DOI: 10.1177/1724600820925095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Wang R, Lin N, Mao B, Wu Q. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals. J Cancer Res Clin Oncol 2021. [PMID: 34297207 DOI: 10.1007/s00432-021-03716-1] [Reference Citation Analysis]
16 Helmberger T. The evolution of interventional oncology in the 21st century. Br J Radiol 2020;93:20200112. [PMID: 32706978 DOI: 10.1259/bjr.20200112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer 2020;8:e000340. [PMID: 32461345 DOI: 10.1136/jitc-2019-000340] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
19 Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol 2021;27:144-56. [PMID: 33280350 DOI: 10.3350/cmh.2020.0095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Yin W, Xu J, Li C, Dai X, Wu T, Wen J. Plantamajoside inhibits the proliferation and epithelial-to-mesenchymal transition in hepatocellular carcinoma cells via modulating hypoxia-inducible factor-1α-dependent gene expression. Cell Biol Int 2020;44:1616-27. [PMID: 32239594 DOI: 10.1002/cbin.11354] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
22 Tai D, Choo SP, Chew V. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. Cancers (Basel) 2019;11:E1926. [PMID: 31816940 DOI: 10.3390/cancers11121926] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
23 Kon E, Benhar I. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success. Drug Resistance Updates 2019;45:13-29. [DOI: 10.1016/j.drup.2019.07.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
24 Zhou D, Luan J, Huang C, Li J. Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe? Gut Liver 2021;15:500-16. [PMID: 33087588 DOI: 10.5009/gnl20223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
25 Rim CH, Lee HY, Kim JS, Kim H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? Int J Radiat Biol 2021;97:111-9. [PMID: 33253598 DOI: 10.1080/09553002.2021.1857453] [Reference Citation Analysis]
26 Lee HA, Park S, Seo YS, Yoon WS, Shin I, Rim CH. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis. J Hepatobiliary Pancreat Sci. [DOI: 10.1002/jhbp.865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 69.0] [Reference Citation Analysis]
28 Kim N, Yu JI, Park HC, Yoo GS, Choi C, Hong JY, Lim HY, Lee J, Choi MS, Lee JE, Kim K. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother 2021;70:1593-603. [PMID: 33231725 DOI: 10.1007/s00262-020-02794-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Dosset M, Joseph EL, Rivera Vargas T, Apetoh L. Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells 2020;9:E1727. [PMID: 32707692 DOI: 10.3390/cells9071727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]
31 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
32 Kim JW, Lee IJ. Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma. Clin Mol Hepatol 2021;27:103-6. [PMID: 33317257 DOI: 10.3350/cmh.2020.0297] [Reference Citation Analysis]
33 Sun N, Zhang J, Li B, Li A, Lv M, Zhang C. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review. Medicine (Baltimore) 2021;100:e27987. [PMID: 34889243 DOI: 10.1097/MD.0000000000027987] [Reference Citation Analysis]
34 Lee HA, Rim CH. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. J Hepatocell Carcinoma 2020;7:435-46. [PMID: 33376712 DOI: 10.2147/JHC.S285357] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Park S, Yoon WS, Jang MH, Rim CH. Clinical efficacy of external beam radiotherapy complementing incomplete transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Biol 2020;96:1541-9. [PMID: 32990486 DOI: 10.1080/09553002.2020.1830316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Yoo GS, Yu JI, Park HC. Current role of proton beam therapy in patients with hepatocellular carcinoma. Int J Gastrointest Interv 2021;10:175-82. [DOI: 10.18528/ijgii210043] [Reference Citation Analysis]
37 Chen LC, Lin HY, Hung SK, Chiou WY, Lee MS. Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World J Gastroenterol 2021; 27(20): 2434-2457 [PMID: 34092968 DOI: 10.3748/wjg.v27.i20.2434] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
38 Nesbitt H, Logan K, Thomas K, Callan B, Gao J, McKaig T, Taylor M, Love M, Stride E, McHale AP, Callan JF. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer Lett 2021;517:88-95. [PMID: 34119606 DOI: 10.1016/j.canlet.2021.06.003] [Reference Citation Analysis]
39 Xia Y, Lin X, Cheng Y, Xu H, Zeng J, Xie W, Wang M, Sun Y. Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. Front Genet 2022;13:938796. [DOI: 10.3389/fgene.2022.938796] [Reference Citation Analysis]